Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

Cardiovascular risk reduction with icosapent ethyl

Open access
Patel, Parth N., Patel, Siddharth M., Bhatt, Deepak L. · 2019 · Current Opinion in Cardiology

Abstract

PURPOSE OF REVIEW: Residual risk for atherosclerotic cardiovascular disease (ASCVD) persists even among patients with optimal low-density lipoprotein cholesterol (LDL-C) levels. Randomized trials attempting to modulate other lipids beyond LDL-C have failed to demonstrate significant reductions in ischemic events. RECENT FINDINGS: Mounting evidence suggests that triglyceride elevation is an independent risk factor for ASCVD. Though trials of triglyceride-lowering therapy in the statin era have failed to provide protection from ASCVD events, subgroup analyses have revealed that those with the highest triglycerides at time of enrollment appeared to receive the greatest clinical benefit. REDUCE-IT was a trial that enrolled patients with high triglycerides despite having goal LDL-C levels on statin therapy. Treatment with icosapent ethyl, a highly purified omega-3 fatty acid (OM3FA), eicosapentaenoic acid ethyl ester, provided a 25% relative risk reduction for the primary composite cardiovascular endpoint (hazard ratio 0.75, 95% CI 0.68--0.83; P = 0.00000001), as well as a 30% relative risk reduction in total ischemic events (P = 0.00000000036). SUMMARY: Icosapent ethyl was rigorously shown to decrease residual risk for cardiovascular events, though the benefits seen were likely because of mechanisms beyond mere triglyceride lowering. Clinical application of icosapent ethyl in this cohort of patients with residual risk is urgently needed.

Overview

Integrity signals

Registry

Crossref · 10.1097/hco.0000000000000678

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 52 references

Cited by

See all 34

Metadata

Authors
Patel, P. N., Patel, S. M., & Bhatt, D. L.
Affiliations
Brigham and Women's Hospital (US)
Corresponding author
Bhatt, Deepak L.
Venue
Current Opinion in Cardiology
Published
2019-11
Volume
34
Issue
6
Pages
721-727
ISSN
0268-4705 (ISSN-L)
OpenAlex
W2970436550
Cited by
33
References
52
Citations by year
2026: 1 · 2025: 1 · 2024: 2 · 2023: 5 · 2022: 1 · 2021: 12 · 2020: 8 · 2019: 3
FWCI
0.81
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Current Opinion in Cardiology (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Keywords
icosapent ethyl, omega-3 fatty acids, eicosapentaenoic acid, atherosclerotic cardiovascular disease, residual cardiovascular risk, triglyceride elevation, LDL cholesterol, statin therapy, ischemic events, REDUCE-IT trial, triglyceride-lowering therapy
MeSH terms
Cardiovascular Diseases, Humans, Risk Factors, Triglycerides, Eicosapentaenoic Acid, Hypertriglyceridemia, Randomized Controlled Trials as Topic, Risk Reduction Behavior, Atherosclerosis, Lipid Regulating Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cardiovascular risk reduction with icosapent ethyl. https://app.cochat.ai/papers/10.1097/hco.0000000000000678
The paper
Patel, P. N., Patel, S. M., & Bhatt, D. L. (2019). Cardiovascular risk reduction with icosapent ethyl. Current Opinion in Cardiology. https://doi.org/10.1097/hco.0000000000000678

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.